Tuberculosis remains one of the most lethal communicable diseases in the world, with 10 million new cases and 1.5 million deaths per year.
Within the current portfolio of vaccines under development worldwide against tuberculosis, our MTBVAC vaccine is one of the strongest and most promising in the opinion of experts worldwide.
MTBVAC, is a live attenuated vaccine of M. tuberculosis (Mycobacterium tuberculosis) designed by the genetic research group of Dr. Carlos Martin Montañés of the Department of Microbiology at the University of Zaragoza and Brigitte Gicquel at the Institut Pasteur in Paris.
- MTBVAC PRIME
Tuberculosis vaccine for newborns
- MTBVAC BOOSTER
Tuberculosis vaccine for adolescents and adults
Biofabri is responsible for the manufacture of MTBVAC as a live attenuated lyophilized vaccine and aims to license MTBVAC against tuberculosis in both, adults and newborns.
The MTBVAC vaccine has recently finished Phase 2 clinical trials with both newborns and adults in South Africa, one of the largest endemic countries.
Phase 3 efficacy study is expected in H1 2022.
Biofabri is also working on the development of other new and innovative biologicals.